How New Gene Therapy Innovations Could Accelerate Treatment for Bardet-Biedl Syndrome and Inherited Retinal Diseases

At this year’s Gene Therapy for Ophthalmic Disorders Summit, one message came through loud and clear: retinal gene therapy is advancing faster than ever before — and the innovations emerging today could directly shape the future of treatment for Bardet-Biedl Syndrome (BBS), retinitis pigmentosa (RP), and other inherited retinal diseases. While no single therapy presented at the conference was BBS-specific, the scientific breakthroughs discussed are exactly the kinds of advancements that will make BBS gene therapy safer, stronger, and more likely to succeed. Below, we break down the most meaningful innovations — and why they matter for families who urgently need treatment options. 1. Smarter, More Sensitive Vision Endpoints Traditional vision tests often fail to capture early improvements in rare retinal diseases. At the summit, researchers emphasized modern testing tools now gaining regulatory acceptance: Microperimetry — pinpoints functional sensitivity across the retina Full-field sensitivity testing (FST) — widely used for IRDs with low vision Patient-reported outcomes — captures